Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation

Abstract

The BCR-ABL oncogene encodes an in-frame fusion protein containing N-terminal sequences derived from Bcr and C-terminal sequences derived from Abl. Bcr contains a centrally located Rho-specific guanine nucleotide exchange factor (RhoGEF) domain that is retained within p210 Bcr-Abl. Although this domain is subject to autoinhibition in the context of Bcr, here we show that it is constitutively activated in p210 Bcr-Abl. p210 Bcr-Abl can stimulate RhoA activation independently of its tyrosine kinase activity, and mutations within the RhoGEF domain that are predicted to eliminate RhoGEF activity inhibit RhoA activation. The RhoGEF mutant of p210 Bcr-Abl does not affect the tyrosine kinase activity of the molecule, nor the ability of p210 Bcr-Abl to interact with XPB through the RhoGEF domain. Despite retaining normal levels of tyrosine kinase activity, the RhoGEF mutant of p210 Bcr-Abl is impaired in transforming activity as measured by anchorage-independent growth. However, the mutant is still able to confer the phenotype of growth factor independence in myeloid cells, suggesting that some, but not all parameters of p210 Bcr-Abl transformation, are dependent upon a catalytically active RhoGEF domain. Collectively, these observations identify a gain-of-function activity attributable to the RhoGEF domain of p210 Bcr-Abl that is required to support the transformed phenotype.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bassermann F, Jahn T, Miething C, Seipel P, Bai RY, Coutinho S et al. (2002). Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. J Biol Chem 277: 12437–12445.

    Article  CAS  PubMed  Google Scholar 

  • Chuang TH, Xu X, Kaartinen V, Heisterkamp N, Groffen J, Bokoch GM . (1995). Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. Proc Natl Acad Sci USA 92: 10282–10286.

    Article  CAS  PubMed  Google Scholar 

  • Daley GQ, Baltimore D . (1998). Transformation of an interleukin 3-dependent hematopoietic cell-line by the chronic myelogenous leukemia-specific p210 Bcr-Abl protein. Proc Natl Acad Sci USA 85: 9312–9316.

    Article  Google Scholar 

  • Han J, Das B, Wei W, Van Aelst L, Mosteller RD, Khosravi-Far R et al. (1997). Lck regulates Vav activation of members of the Rho family of GTPases. Mol Cell Biol 17: 1346–1353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Harnois T, Constantin B, Rioux A, Grenioux E, Kitzis A, Bourmeyster N . (2003). Differential interaction and activation of Rho family GTPases by p210bcr−abl and p190bcr−abl. Oncogene 22: 6445–6454.

    Article  CAS  PubMed  Google Scholar 

  • Korus M, Mahon GM, Cheng L, Whitehead IP . (2002). p38 MAPK-mediated activation of NF-κB by the RhoGEF domain of Bcr. Oncogene 21: 4601–4612.

    Article  CAS  PubMed  Google Scholar 

  • Lugo TG, Pendergast AM, Muller AJ, Witte ON . (1990). Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079–1082.

    Article  CAS  PubMed  Google Scholar 

  • Lugo TG, Witte ON . (1989). The Bcr-Abl oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol 9: 1263–1270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mahon GM, Wang Y, Korus M, Kostenko E, Cheng L, Sun T et al. (2003). The c-Myc oncoprotein interacts with Bcr. Curr Biol 13: 437–441.

    Article  CAS  PubMed  Google Scholar 

  • McWhirter JR, Wang JY . (1991). Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 11: 1553–1565.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McWhirter JR, Wang JY . (1993). An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 12: 1533–1546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Muller AJ, Young JC, Pendergast AM, Pondel M, Landau NR, Littman DR et al. (1991). BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol 11: 1785–1792.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Olabisi OO, Mahon GM, Kostenko EV, Liu Z, Ozer HL, Whitehead IP . (2006). Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover. Cancer Res 66: 6250–6257.

    Article  CAS  PubMed  Google Scholar 

  • Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON . (1991). BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66: 161–171.

    Article  CAS  PubMed  Google Scholar 

  • Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N et al. (1993). BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175–185.

    Article  CAS  PubMed  Google Scholar 

  • Ramaraj P, Singh H, Niu N, Chu S, Holtz M, Yee JK et al. (2004). Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res 64: 5322–5331.

    Article  CAS  PubMed  Google Scholar 

  • Renshaw MW, McWhirter JR, Wang JY . (1995). The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation. Mol Cell Biol 15: 1286–1293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ridley AJ . (1995). Rho-related proteins: actin cytoskeleton and cell cycle. Curr Opin Genet Dev 5: 24–30.

    Article  CAS  PubMed  Google Scholar 

  • Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA et al. (1997). BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 100: 46–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shtivelman E, Lifshitz B, Gale RP, Canaani E . (1985). Fused transcript of abl and bcr genes in chronic melogenous leukaemia. Nature 315: 550–554.

    Article  CAS  PubMed  Google Scholar 

  • Skorski T, Wlodarski P, Daheron L, Salomoni P, Nieborowska-Skorska M, Majewski M et al. (1998). BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci USA 95: 11858–11862.

    Article  CAS  PubMed  Google Scholar 

  • Takeda N, Shibuya M, Maru Y . (1999). The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci USA 96: 203–207.

    Article  CAS  PubMed  Google Scholar 

  • ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N et al. (1994). Cellular interactions of CRKL, an SH2–SH3 adaptor protein. Cancer Res 54: 2563–2567.

    CAS  PubMed  Google Scholar 

  • Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, Pear WS . (2002). BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood 99: 4122–4130.

    Article  CAS  PubMed  Google Scholar 

  • Whitehead IP, Campbell S, Rossman KL, Der CJ . (1997). Dbl family proteins. Biochim Biophys Acta 1332: F1–F23.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Public Health Service grant CA097066 (IPW) from the National Cancer Institute and AG04821 (HLO) from the National Institute of Aging. PL Rodriguez and NL Pannucci are recipients of fellowships from the New Jersey Commission for Cancer research.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to I P Whitehead.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sahay, S., Pannucci, N., Mahon, G. et al. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene 27, 2064–2071 (2008). https://doi.org/10.1038/sj.onc.1210841

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1210841

Keywords

This article is cited by

Search

Quick links